

Are You or Your Child Facing Challenges Due to CAH?

Consider Joining a Clinical
Research Study



The Balance-CAH Study is currently enrolling children and adolescents diagnosed with classic CAH to take part in research of an investigational study drug called atumelnant.

Atumelnant is an investigational study drug, which means it has not been approved by any regulatory authority and is still under investigation as a potential treatment for CAH.

Those who qualify will receive the assigned study treatment (study drug or placebo) and all study procedures at no cost. Additionally, reasonable costs for travel may be reimbursed when you visit the research center for study visits. This study will last about 9 months with up to 16 visits, 5 of which may be done by telephone.

To participate in this study, you or your child must:

- Be 1 to 17 years of age
- Have received a diagnosis of classic CAH
- Be on a stable glucocorticoid regimen
 - Includes: modified-release hydrocortisone, cortisone acetate, prednisolone, prednisone, methylprednisolone, and dexamethasone



To learn more or to see if you or your child may qualify for the
Balance-CAH Study, scan the QR code or visit CrineticsCAH.com.

